Blog
RSS FeedPosted by Michael Wonder on 25 Nov 2015
NICE consults on ovarian cancer treatments draft guidance
24 November 2015 - The draft guidance gives provisional recommendations on whether paclitaxel, pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, trabectedin and ...
Posted by Michael Wonder on 25 Nov 2015
NICE draft guidance recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement
23 November 2015 - In final draft guidance as part of its Highly Specialised Technologies Programme, NICE has provisionally recommended Elosulfase ...
Posted by Michael Wonder on 20 Nov 2015
Consultation now open on plans to reform Cancer Drugs Fund
19 November 2015 - NHS England and NICE have begun a consultation on a new Cancer Drugs Fund. ...
Posted by Michael Wonder on 19 Nov 2015
NICE, NHS England consult on Cancer Drugs Fund revamp
19 November 2015 - Long-awaited plans for the future of England’s Cancer Drugs Fund have now been unveiled, with proposals centred ...
Posted by Michael Wonder on 19 Nov 2015
NICE OK's restricted use of Bayer's prostate cancer drug Xofigo
19 November 2015 - NICE will this morning issue a Final Appraisal Determination recommending the use of Bayer’s Xofigo on the ...
Posted by Michael Wonder on 19 Nov 2015
NICE issues draft guidance on evolocumab for lipid disorder
18 November 2015 - NICE has published draft guidance not recommending evolocumab (Repatha, Amgen) as an option for people with high ...
Posted by Michael Wonder on 18 Nov 2015
Amgen's cholesterol-buster Repatha turned down for NHS use
18 November 2015 - NICE has turned down Amgen’s Repatha - the world’s first approved PCSK9 inhibitor - as an option ...
Posted by Michael Wonder on 18 Nov 2015
NICE says 'no' to personalised bowel cancer drugs
18 November 2015 - NICE has published interim guidance barring patients with advanced bowel cancer from routine NHS access to Merck ...
Posted by Michael Wonder on 17 Nov 2015
NICE: Kadcyla price still too high
17 November 2015 - Although retained for use through the Cancer Drugs Fund, Roche’s breast cancer combination treatment, Kadcyla (trastuzumab emtansine), ...
Posted by Michael Wonder on 05 Nov 2015
NICE not in favour of drug for neuroblastoma
5 November 2015 - It looks like children and adolescents with neuroblastoma will not be able to access United Therapeutics’ Unituxin ...
Posted by Michael Wonder on 04 Nov 2015
NICE gives green light to dry eye disease treatment in final draft guidance
4 November 2015 - NICE has published final draft guidance recommending ciclosporin (Ikervis) manufactured by Santen Pharmaceutical) for treating severe keratitis ...
Posted by Michael Wonder on 28 Oct 2015
NICE publishes final drug recommendations for the treatment of 3 separate medical conditions
28 October 2015 - The National Institute for Health and Care Excellence has published its final recommendations for paclitaxel (nanoparticle ...
Posted by Michael Wonder on 22 Oct 2015
NICE draft guidance recommends treatments for arthritis in children
21 October 2015 - Health care guidance body NICE has today published final draft guidance recommending 4 drugs for treating a ...
Posted by Michael Wonder on 22 Oct 2015
NICE issues draft guidance on ezetimibe for primary hypercholesterolaemia
20 October 2015 - NICE has today published draft guidance recommending ezetimibe (Ezetrol, Merck Sharp & Dohme) as an option for ...
Posted by Michael Wonder on 22 Oct 2015
NICE approval of new hepatitis drug could result in £700m bill for NHS
21 October 2015 - The National Institute for Health and Care Excellence has approved another treatment for hepatitis C, presenting NHS ...